Optimi Health AI Stock Analysis
Want to see TSE:OPTI full AI Analyst Report?
Optimi Health (OPTI) AI Stock Analysis
Optimi Health
(CNQX:OPTI)
The overall score of 37 reflects a company in severe financial distress with a uniformly negative outlook across all evaluated components. The most significant factor is the deteriorating financial performance, marked by collapsing revenue, deeply negative margins, and a high cash burn rate that is rapidly eroding equity. This is compounded by a bearish technical trend with the stock in a sustained downtrend and deeply oversold conditions. The negative P/E ratio and lack of dividends offer no valuation support. The company faces high risk of financial distress without a significant capital infusion or operational turnaround.
Optimi Health (OPTI) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 13.17M
- Dividend Yield
- ―
- Average Volume (3M)
- 5,100
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 1.31
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Canada
- Employees
- 9
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Optimi Health Business Overview & Revenue Model
Company Description
Optimi Health Corp. focuses on developing an integrated brand of functional mushrooms specifically for the Canadian health and wellness food markets. The company manages the entire process from the cultivation and extraction to the processing and dis...
How the Company Makes Money
Optimi Health makes money primarily by selling mushroom-related products and services across a few core channels: (1) Product sales from cultivation and processing: Revenue is generated through the production and sale of functional mushrooms and, whe...
Optimi Health Financial Statement Overview
Summary
Financial health is critically weak. The company is pre-revenue with a 24% TTM revenue decline, gross margins have collapsed to -1,323%, and net losses are accelerating, eroding shareholder equity. The debt-to-equity ratio has spiked to 1.86, adding significant financial risk. The only mitigating factor is a 61% improvement in free cash flow, suggesting cost-cutting, but this does not offset the severe operational and solvency concerns.
Income Statement
8Very NegativeBalance Sheet
35NegativeCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 175.67K | 426.30K | 389.85K | 181.09K | 80.72K | 0 |
| Gross Profit | -3.68M | -2.07M | 270.91K | -157.04K | 53.92K | -47.12K |
| EBITDA | -4.93M | -2.23M | -4.74M | -4.42M | -7.03M | -5.95M |
| Net Income | -6.90M | -3.71M | -6.04M | -5.19M | -7.38M | -6.04M |
Balance Sheet | ||||||
| Total Assets | 25.86M | 15.21M | 14.55M | 16.49M | 16.82M | 23.46M |
| Cash, Cash Equivalents and Short-Term Investments | 13.07M | 1.15M | 103.66K | 1.34M | 1.89M | 12.43M |
| Total Debt | 5.14M | 6.68M | 2.75M | 1.71M | 157.58K | 250.84K |
| Total Liabilities | 8.22M | 8.64M | 4.98M | 3.28M | 797.66K | 2.40M |
| Stockholders Equity | 17.64M | 6.57M | 9.58M | 13.21M | 16.02M | 21.07M |
Cash Flow | ||||||
| Free Cash Flow | -5.31M | -2.72M | -4.43M | -4.41M | -11.73M | -10.96M |
| Operating Cash Flow | -5.20M | -2.63M | -4.28M | -3.60M | -4.58M | -6.02M |
| Investing Cash Flow | -109.68K | -88.38K | -154.02K | -706.02K | -3.15M | -9.19M |
| Financing Cash Flow | 18.29M | 3.76M | 3.19M | 3.76M | 1.19M | 19.18M |
Optimi Health Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OPTI, the sentiment is Negative. The current price of 2.30 is below the 20-day moving average (MA) of 3.27, below the 50-day MA of 4.91, and below the 200-day MA of 7.28, indicating a bearish trend. The MACD of -0.63 indicates Negative momentum. The RSI at 20.75 is Positive, neither overbought nor oversold. The STOCH value of 2.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:OPTI.
Optimi Health Peers Comparison
Overall Rating
TSE:LABS55Neutral
TSE:ROMJ49Neutral
TSE:AVCN48Neutral
TSE:DOSE39Underperform
TSE:PCLO39Underperform
TSE:OPTI37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 55Neutral | CAD 25.63M | -9.23 | -7.66% | ― | -9.31% | 66.84% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | CAD 23.65M | -5.25 | -10.97% | ― | 16.91% | -244.25% | |
| 48Neutral | CAD 11.42M | -3.86 | -65.40% | ― | -3.32% | -34.15% | |
| 39Underperform | CAD 13.09M | -4.04 | 42.51% | ― | -19.31% | 34.45% | |
| 39Underperform | CAD 6.54M | -1.87 | 28.59% | ― | 0.90% | 57.73% | |
| 37Underperform | CAD 13.17M | -1.18 | -84.23% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:OPTI | Optimi Health Corp. | 2.30 | -8.35 | -78.40% | |
| TSE:DOSE | Rapid Dose Therapeutics Corp | 0.10 | -0.08 | -44.12% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.06 | -0.01 | -7.69% | |
| TSE:PCLO | Pharmacielo | 0.04 | -0.01 | -22.22% | |
| TSE:ROMJ | Rubicon Organics | 0.35 | -0.10 | -22.22% | |
| TSE:AVCN | Avicanna Inc | 0.09 | -0.15 | -64.58% |
Optimi Health Corporate Events
Optimi Health Sets Up Australian Subsidiary to Drive Psychedelic Drug Distribution
PositiveOptimi Health has created a wholly owned subsidiary, Optimi Australia Pty Ltd, to serve as its dedicated distribution and business development arm in Australia. The new entity will oversee sales, distribution, and prescriber relationships for the com...
Optimi Health Readies MDMA Supply for Global PTSD Trials and Australian Market
PositiveOptimi Health Corp., a Vancouver-based commercial-stage pharmaceutical manufacturer, produces GMP-grade MDMA and psilocybin drug products for regulated mental health therapies. The Health Canada-licensed company supplies active pharmaceutical ingredi...
Optimi Health Adds Veteran Finance Executive Melanie Pump to Board
PositiveOptimi Health has appointed experienced finance executive Melanie Pump to its Board of Directors, adding more than 25 years of leadership across technology, digital infrastructure, software, fintech and emerging growth companies. The company’s CEO hi...
Optimi Health Aligns Clinical and Commercial Psilocybin Supply With New cGMP Batch
PositiveOptimi Health has completed and quality released an in-house cGMP batch of 5 mg naturally derived psilocybin capsules under its Health Canada Drug Establishment Licence, intended for use in a Phase 2 trial for major depressive disorder and for commer...
Optimi Health to Launch Phase 3 MDMA Trial for PTSD in Veterans and Frontline Workers
PositiveOptimi Health plans to launch a Health Canada-authorized Phase 3 clinical trial in 2027 to evaluate MDMA-assisted therapy for post-traumatic stress disorder in up to 100 veterans and frontline workers across multiple sites in Canada. Participants wil...
Optimi Health to Present at H.C. Wainwright Global Investment Conference
PositiveOptimi Health Corp., a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, focuses on GMP-grade MDMA and botanical psilocybin therapies for mental health conditions. The company operates Health Canada-licensed, GMP-co...
Optimi Health Sets Up US$100 Million Equity Line for Psychedelic Drug Expansion
PositiveOptimi Health Corp. has established a discretionary equity line of credit of up to US$100 million with Seven Knots, LLC, allowing the company to sell common shares at its own discretion, subject to pricing formulas, per-draw limits, ownership caps, a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 02, 2026